Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review
Background: Pancreatic cancer is one of the most deadly malignancies in the world. It is characterized by rapid progression and a very poor prognosis. The five-year survival rate of pancreatic cancer in China is only 7.2%, which is the lowest among all cancers and the use of combined paclitaxel albu...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2023.1167470/full |
| _version_ | 1797826734403354624 |
|---|---|
| author | Xiaolong Liu Feimin Yang Dunmao Jia Xinyu Dong Yizhuo Zhang Zhengrong Wu |
| author_facet | Xiaolong Liu Feimin Yang Dunmao Jia Xinyu Dong Yizhuo Zhang Zhengrong Wu |
| author_sort | Xiaolong Liu |
| collection | DOAJ |
| description | Background: Pancreatic cancer is one of the most deadly malignancies in the world. It is characterized by rapid progression and a very poor prognosis. The five-year survival rate of pancreatic cancer in China is only 7.2%, which is the lowest among all cancers and the use of combined paclitaxel albumin, capecitabine, and digital has been the clinical standard treatment for advanced pancreatic cancer since 1997. Also, the application of multidrug combinations is often limited by the toxicity of chemotherapy. Therefore, there is an urgent need for a more appropriate and less toxic treatment modality for pancreatic cancer.Case presentation: The patient was a 79-year-old woman, admitted to the hospital with a diagnosis of unresectable locally advanced pancreatic cancer (T3N0M0, stage IIA), with its imaging showing overgrowth of SMV involvement and unresectable reconstruction of the posterior vein after evaluation. As the patient refused chemotherapy, lenvatinib (8 mg/time, qd) and icaritin soft capsules (three tablets/time, bid) were recommended according to our past experience and a few clinical research cases. The tumor lesion was greatly reduced by 57.5% after the treatment, and the extent of vascular involvement also decreased. The aforementioned medication resulted in a significant downstaging of the patient’s tumor.Conclusion: Better results were achieved in the treatment with icaritin soft capsules and lenvatinib in this case. Because of its less toxic effect on the liver and kidney and bone marrow suppression, it was suitable to combine icaritin soft capsules with targeted drugs for treating intermediate and advanced malignancies, which brings hope to patients who cannot or refuse to take chemotherapy. |
| first_indexed | 2024-04-09T12:37:01Z |
| format | Article |
| id | doaj.art-e7d0223525064762b214dde857f9cf36 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-09T12:37:01Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-e7d0223525064762b214dde857f9cf362023-05-15T12:32:00ZengFrontiers Media S.A.Frontiers in Genetics1664-80212023-04-011410.3389/fgene.2023.11674701167470Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature reviewXiaolong Liu0Feimin Yang1Dunmao Jia2Xinyu Dong3Yizhuo Zhang4Zhengrong Wu5Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Nursing, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of General Surgery, Affiliated Run Run Shaw Hospital, Jiangshan Branch, Harbin Medical University, Quzhou, ChinaDepartment of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaBackground: Pancreatic cancer is one of the most deadly malignancies in the world. It is characterized by rapid progression and a very poor prognosis. The five-year survival rate of pancreatic cancer in China is only 7.2%, which is the lowest among all cancers and the use of combined paclitaxel albumin, capecitabine, and digital has been the clinical standard treatment for advanced pancreatic cancer since 1997. Also, the application of multidrug combinations is often limited by the toxicity of chemotherapy. Therefore, there is an urgent need for a more appropriate and less toxic treatment modality for pancreatic cancer.Case presentation: The patient was a 79-year-old woman, admitted to the hospital with a diagnosis of unresectable locally advanced pancreatic cancer (T3N0M0, stage IIA), with its imaging showing overgrowth of SMV involvement and unresectable reconstruction of the posterior vein after evaluation. As the patient refused chemotherapy, lenvatinib (8 mg/time, qd) and icaritin soft capsules (three tablets/time, bid) were recommended according to our past experience and a few clinical research cases. The tumor lesion was greatly reduced by 57.5% after the treatment, and the extent of vascular involvement also decreased. The aforementioned medication resulted in a significant downstaging of the patient’s tumor.Conclusion: Better results were achieved in the treatment with icaritin soft capsules and lenvatinib in this case. Because of its less toxic effect on the liver and kidney and bone marrow suppression, it was suitable to combine icaritin soft capsules with targeted drugs for treating intermediate and advanced malignancies, which brings hope to patients who cannot or refuse to take chemotherapy.https://www.frontiersin.org/articles/10.3389/fgene.2023.1167470/fullicaritin soft capsuleslenvatinibadvanced pancreatic cancercombined treatmenttumor downstaging |
| spellingShingle | Xiaolong Liu Feimin Yang Dunmao Jia Xinyu Dong Yizhuo Zhang Zhengrong Wu Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review Frontiers in Genetics icaritin soft capsules lenvatinib advanced pancreatic cancer combined treatment tumor downstaging |
| title | Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review |
| title_full | Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review |
| title_fullStr | Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review |
| title_full_unstemmed | Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review |
| title_short | Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review |
| title_sort | case report a case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive pr and stage reduction in unresectable locally progressive pancreatic cancer and a literature review |
| topic | icaritin soft capsules lenvatinib advanced pancreatic cancer combined treatment tumor downstaging |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2023.1167470/full |
| work_keys_str_mv | AT xiaolongliu casereportacasestudyonthetreatmentusingicaritinsoftcapsulesincombinationwithlenvatinibachievingimpressiveprandstagereductioninunresectablelocallyprogressivepancreaticcancerandaliteraturereview AT feiminyang casereportacasestudyonthetreatmentusingicaritinsoftcapsulesincombinationwithlenvatinibachievingimpressiveprandstagereductioninunresectablelocallyprogressivepancreaticcancerandaliteraturereview AT dunmaojia casereportacasestudyonthetreatmentusingicaritinsoftcapsulesincombinationwithlenvatinibachievingimpressiveprandstagereductioninunresectablelocallyprogressivepancreaticcancerandaliteraturereview AT xinyudong casereportacasestudyonthetreatmentusingicaritinsoftcapsulesincombinationwithlenvatinibachievingimpressiveprandstagereductioninunresectablelocallyprogressivepancreaticcancerandaliteraturereview AT yizhuozhang casereportacasestudyonthetreatmentusingicaritinsoftcapsulesincombinationwithlenvatinibachievingimpressiveprandstagereductioninunresectablelocallyprogressivepancreaticcancerandaliteraturereview AT zhengrongwu casereportacasestudyonthetreatmentusingicaritinsoftcapsulesincombinationwithlenvatinibachievingimpressiveprandstagereductioninunresectablelocallyprogressivepancreaticcancerandaliteraturereview |